TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 327057

Group type: EXPERIMENTAL
Intervention: Fenfluramine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined doses of Fenfluramine and Dextroamphetamine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Postdrug changes
Number of subjects: 20
Study: 31895437

Group type: EXPERIMENTAL
Intervention: Sertraline hydrochloride for 8 weeks
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Both groups (Sertraline and Placebo)
Number of subjects: 221
Study: 31511044

Group type: EXPERIMENTAL
Intervention: Leucine-enriched essential amino acid (L-EAA) supplementation (5 g L-EAA five times per day for up to 14 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standard feed only (control group)
Number of subjects: 8
Study: 28045286

Group type: EXPERIMENTAL
Intervention: panic‐focused psychodynamic psychotherapy, cognitive‐behavioral therapy, or applied relaxation therapy (24 twice‐weekly sessions)
Number of subjects: 130
Study: 26283667

Group type: EXPERIMENTAL
Intervention: AVERT intervention (specific details not provided)
Number of subjects: 1158
Study: 23849242

Group type: EXPERIMENTAL
Intervention: Combined exercise and psycho-education intervention (EP)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Exercise only (E)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Waiting list control condition (WLC)
Number of subjects: 161
Study: 21266669

Group type: EXPERIMENTAL
Intervention: Acipimox (500 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Metabolic syndrome serum
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Insulin immunodepletion
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Acipimox (5-500 μM)
Number of subjects: 19
Study: 19860922

Group type: EXPERIMENTAL
Intervention: Phase 2 white bean extract (powder) at 3000 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Phase 2 white bean extract (capsule) at 2000 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Phase 2 white bean extract (capsule) at 3000 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Phase 2 white bean extract (powder) at 1500 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Phase 2 white bean extract (powder) at 2000 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: White bread (control)
Number of subjects: 13
Study: 16601747

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser capsulotomy (YLC)
Number of subjects: 158
Study: 15217941

Group type: EXPERIMENTAL
Intervention: S-1 with food (35 mg/m2)
Number of subjects: 18

Group type: COMPARATOR
Intervention: S-1 without food (35 mg/m2)
Number of subjects: 18
Study: 11209118

Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg/day for 12 weeks
Number of subjects: 101

Group type: COMPARATOR
Intervention: Itraconazole (pulse) 200 mg twice a day for 1 week, given for 3 pulses
Number of subjects: 101
Study: 11263297

Group type: EXPERIMENTAL
Intervention: Positive p53 expression in advanced stage NSCLC
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Positive Hras expression
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Abnormal DI and PI
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Expression rates of c-erbB2 and PCNA
Number of subjects: 137
Study: 8067598

Group type: EXPERIMENTAL
Intervention: 200 micrograms of fluticasone propionate once daily
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: 100 micrograms of fluticasone propionate twice daily
Number of subjects: 416

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 416
Study: 2897912

Group type: EXPERIMENTAL
Intervention: Pancuronium (single bolus 0.95 mg kg‐1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Atracurium (single bolus 0.53 mg kg‐1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Vecuronium (single bolus 0.07 mg kg‐1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Pancuronium (divided doses 0.15 mg kg‐1, 3 min before 0.08 mg kg‐1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Atracurium (divided doses 0.07 mg kg‐1, 3 min before 0.46 mg kg‐1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Vecuronium (divided doses 0.01 mg kg‐1, 3 min before 0.06 mg kg‐1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Succinylcholine (1 mg kg‐1)
Number of subjects: 80
Study: 1093330

Group type: EXPERIMENTAL
Intervention: Sch 1000 (Atrovent) 0.02 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sch 1000 (Atrovent) 0.08 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30882777

Group type: EXPERIMENTAL
Intervention: Self-immersed perspective
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Third-person perspective
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exemplar perspective
Number of subjects: 0
Study: 28544460

Group type: EXPERIMENTAL
Intervention: Inogen One G2 POC
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oxygen cylinder
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: EverGo POC
Number of subjects: 20
Study: 26109589

Group type: EXPERIMENTAL
Intervention: apixaban (5 mg twice daily)
Number of subjects: 7392

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7392
Study: 23886150

Group type: EXPERIMENTAL
Intervention: CIK cell therapy (5 courses over 18 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no CIK cell therapy)
Number of subjects: 0
Study: 22779193

Group type: EXPERIMENTAL
Intervention: Naoxintong capsule
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tongxinluo capsule (Control)
Number of subjects: 0
Study: 18547693

Group type: EXPERIMENTAL
Intervention: Use of a chart for extraction instruments and techniques
Number of subjects: 0

Group type: COMPARATOR
Intervention: No chart for extraction instruments and techniques (control)
Number of subjects: 0
Study: 17290150

Group type: EXPERIMENTAL
Intervention: Probiotics (n = 7)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 13
Study: 14978787

Group type: EXPERIMENTAL
Intervention: Right prefrontal slow repetitive transcranial magnetic stimulation (rTMS) at 1 Hz
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11380463

Group type: COMPARATOR
Intervention: Standard ADE (cytarabine, daunorubicin, etoposide)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Sequential ADE (cytarabine, daunorubicin, etoposide)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CSA)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Standard ADE
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Sequential ADE
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 235
Study: 9425485

Group type: EXPERIMENTAL
Intervention: MRI scanning
Number of subjects: 9
Study: 8536027

Group type: EXPERIMENTAL
Intervention: 200 mg pethidine (i. art.) in 50 ml saline
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 200 mg pethidine + 200 micrograms adrenaline (i. art.) in 50 ml saline
Number of subjects: 30

Group type: COMPARATOR
Intervention: 250 mg prilocaine + 200 micrograms adrenaline (i. art.) in a volume of 50 ml
Number of subjects: 30
Study: 3691607

Group type: EXPERIMENTAL
Intervention: Acute AMI 50 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: BUP
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Subchronic AMI + acute BUP
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Subchronic AMI
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29618459

Group type: EXPERIMENTAL
Intervention: Mobile van diagnostic evaluation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Central hospital diagnostic evaluation
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Colposcopy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: In vivo microscopy
Number of subjects: 200
Study: 27272084

Group type: EXPERIMENTAL
Intervention: Face cream containing 4-Hexyl-1, 3-phenylenediol and ascorbic acid-2 glucoside
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 24407192

Group type: EXPERIMENTAL
Intervention: Laparoscopic radical cystectomy (LRC)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Open radical cystectomy (ORC)
Number of subjects: 70
Study: 23796764

Group type: EXPERIMENTAL
Intervention: Ahmed implant
Number of subjects: 238

Group type: COMPARATOR
Intervention: Baerveldt implant
Number of subjects: 238
Study: 20670842

Group type: EXPERIMENTAL
Intervention: Plasma UCN‐1 >or=12.1 pM
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Plasma ET‐1 >or=2.29 pM
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Plasma levels of UCN‐1 and ET‐1
Number of subjects: 154
Study: 18690760

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg/day
Number of subjects: 106

Group type: COMPARATOR
Intervention: Atorvastatin 20 mg/day
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 106
Study: 16160867

Group type: EXPERIMENTAL
Intervention: Insulin glargine (0.4 IU/kg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: NPH insulin (0.4 IU/kg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Insulin ultralente (0.4 IU/kg)
Number of subjects: 36
Study: 12646833

Group type: EXPERIMENTAL
Intervention: Harmonic Scalpel (HS)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Conventional electrocautery (EC)
Number of subjects: 117
Study: 14615229

Group type: EXPERIMENTAL
Intervention: Various electrocardiographic analysis techniques (Fourier analysis, Correlation Dimension Estimation, Approximate Entropy, Discrete Wavelet Transform)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electrocardiographic recordings (approximately 2h in length)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of different analysis methods
Number of subjects: 0
Study: 10221603

Group type: EXPERIMENTAL
Intervention: Gasless laparoscopy
Number of subjects: 103

Group type: COMPARATOR
Intervention: Laparoscopy with pneumoperitoneum
Number of subjects: 103
Study: 7530834

Group type: COMPARATOR
Intervention: WHO-ORS
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Amylyte-ORS
Number of subjects: 144
Study: 2375670

Group type: EXPERIMENTAL
Intervention: EMG biofeedback followed by PET
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EMG biofeedback followed by NMS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NMS followed by PET
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 16 weeks of PET
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 863617

Group type: EXPERIMENTAL
Intervention: Weicon 72
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weicon 38
Number of subjects: 0
Study: 28236777

Group type: EXPERIMENTAL
Intervention: CT scan of the axilla on the same side as the breast cancer
Number of subjects: 291

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 291
Study: 26245776

Group type: EXPERIMENTAL
Intervention: Clobazam (medium and high dosage)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Clobazam (low dosage)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study: 23384975

Group type: EXPERIMENTAL
Intervention: Compounded estrogen cream (Bi‐est (80:20); 2.0 mg) + compounded oral progesterone 100 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Compounded estrogen cream (Bi‐est (80:20); 2.5 mg) + compounded oral progesterone 100 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Compounded estrogen cream (Bi‐est (80:20); 3.0 mg) + compounded oral progesterone 100 mg
Number of subjects: 40
Study: 21279864

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg · kg(‐1) body weight) after a 4-day withdrawal period
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg · kg(‐1) body weight) without a withdrawal period
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 20208464

Group type: EXPERIMENTAL
Intervention: Mental practice combined with physical practice (MP)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Physical practice with cognitive training (Cog)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No training (NOT)
Number of subjects: 12
Study: 16679989

Group type: EXPERIMENTAL
Intervention: Vibration-aided static stretching (device turned on)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Static stretching (device turned off)
Number of subjects: 10
Study: 15621120

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 1000 mg twice a day with stepwise reduction of CNI
Number of subjects: 32

Group type: COMPARATOR
Intervention: Continue current CNI dose
Number of subjects: 32
Study: 11273951

Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg IM (Group K)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (Group C)
Number of subjects: 30
Study: 9678092

Group type: EXPERIMENTAL
Intervention: Low‐dose, gestodene‐containing triphasic oral contraceptive
Number of subjects: 20
Study: 8388583

Group type: EXPERIMENTAL
Intervention: Enoxaparin (EN) 40 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Enoxaparin (EN) 1 mg kg‐1
Number of subjects: 12

Group type: COMPARATOR
Intervention: Unfractionated heparin (UH) 5,000 IU
Number of subjects: 12
Study: 28624553

Group type: COMPARATOR
Intervention: Tamsulosin 0.2 mg daily for 8 weeks
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Naftopidil 75 mg daily for 8 weeks
Number of subjects: 94
Study: 26832834

Group type: EXPERIMENTAL
Intervention: EMD+CAF
Number of subjects: 3

Group type: COMPARATOR
Intervention: CTG+CAF
Number of subjects: 3
Study: 23879344

Group type: EXPERIMENTAL
Intervention: Angled interdental brushes
Number of subjects: 128

Group type: COMPARATOR
Intervention: Straight interdental brushes (standard control)
Number of subjects: 128
Study: 22516884

Group type: EXPERIMENTAL
Intervention: Horticultural therapy (n = 37)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Pain-management program without horticultural therapy (control, n = 42)
Number of subjects: 79
Study: 20189239

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting
Number of subjects: 1713

Group type: COMPARATOR
Intervention: Carotid endarterectomy
Number of subjects: 1713
Study: 18471665

Group type: EXPERIMENTAL
Intervention: $4 instant lottery ticket incentive (Group A)
Number of subjects: 728

Group type: COMPARATOR
Intervention: No incentive (Group B)
Number of subjects: 728
Study: 15735918

Group type: EXPERIMENTAL
Intervention: Whole brain radiotherapy (WBRT)
Number of subjects: 14
Study: 14628714

Group type: EXPERIMENTAL
Intervention: Sentinel node navigation surgery (SNNS)
Number of subjects: 0
Study: 10813593

Group type: EXPERIMENTAL
Intervention: Feeding bradycardia group (12 infants)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (10 infants)
Number of subjects: 12
Study: 8659720

Group type: COMPARATOR
Intervention: Placebo (Group 1, n = 25)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Droperidol 2.5 mg with induction of anesthesia and 1.25 mg 12 h later (Group 2, n = 25)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg with induction (Group 3, n = 25)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ondansetron plus droperidol at the same doses as Groups 3 and 2 (Group 4, n = 25)
Number of subjects: 100
Study: 1899945

Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 204
Study: 6507997

Group type: EXPERIMENTAL
Intervention: Budesonide (400 micrograms/day)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 31146138

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 29292694

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg multiunit pellet system (MUPS) tablets
Number of subjects: 60

Group type: COMPARATOR
Intervention: Esomeprazole 20 mg banded capsules
Number of subjects: 60
Study: 26895919

Group type: EXPERIMENTAL
Intervention: Distraction phase (pager beeped and questions asked)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Quiet phase (uninterrupted task performance)
Number of subjects: 30
Study: 24965218

Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal therapy (NSPT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral hygiene instructions (OHI)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal therapy (NSPT) and Oral hygiene instructions (OHI)
Number of subjects: 40
Study: 21953573

Group type: EXPERIMENTAL
Intervention: Vardenafil 20 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 20470423

Group type: EXPERIMENTAL
Intervention: Group counseling
Number of subjects: 128

Group type: COMPARATOR
Intervention: Individual counseling
Number of subjects: 128
Study: 17701044

Group type: EXPERIMENTAL
Intervention: Transurethral ultrasonography-guided injections of autologous myoblasts and fibroblasts
Number of subjects: 63

Group type: COMPARATOR
Intervention: Transurethral endoscopic injections of collagen
Number of subjects: 63
Study: 15920210

Group type: EXPERIMENTAL
Intervention: Overall mean weighted quality score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Appropriate controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discussions of side effects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomization blinding
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blinding observers to results
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-beta estimates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Absence of important pretreatment clinical predictors
Number of subjects: 0
Study: 11893435

Group type: EXPERIMENTAL
Intervention: Maternal supplementation of antioxidant vitamins (beta-carotene 20 mg, vitamin E 167.8 mg, vitamin C 1000 mg daily until delivery)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control group (7 mother-infant pairs comparable in gestation and birthweight)
Number of subjects: 5
Study: 9451067

Group type: EXPERIMENTAL
Intervention: High flow rate (200 ml/min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low flow rate (100 ml/min)
Number of subjects: 20
Study: 8560537

Group type: EXPERIMENTAL
Intervention: Oral co-amoxiclav
Number of subjects: 101

Group type: COMPARATOR
Intervention: Oral 'conventional' regimen (combination of chloramphenicol, cotrimoxazole, and doxycycline)
Number of subjects: 101
Study: 2172402

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 845296

Group type: EXPERIMENTAL
Intervention: Structured learning sessions designed to teach interviewee verbal skills
Number of subjects: 40

Group type: COMPARATOR
Intervention: Time and attention placebo procedure
Number of subjects: 40
Study: 31345778

Group type: EXPERIMENTAL
Intervention: 500 mg norursodeoxycholic acid
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: 1500 mg norursodeoxycholic acid
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study: 29896930

Group type: EXPERIMENTAL
Intervention: Amino acid infusion (L‐[2,3,3,4,5,5,5,6,6,6‐2 H10 ]leucine at 0.15 μmol/kg fat‐free mass/min)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Amino acid infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fasted state
Number of subjects: 20
Study: 26906703

Group type: EXPERIMENTAL
Intervention: Femtosecond laser‐assisted cataract surgery
Number of subjects: 314

Group type: COMPARATOR
Intervention: Conventional phacoemulsification cataract surgery
Number of subjects: 314
Study: 23570672

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) therapy
Number of subjects: 0
Study: 21553314

Group type: EXPERIMENTAL
Intervention: Compression bandaging
Number of subjects: 21

Group type: COMPARATOR
Intervention: Compression garments
Number of subjects: 21
Study: 21028969

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg of elemental zinc daily for 8 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 17318893

Group type: EXPERIMENTAL
Intervention: Flat tibial insert
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Concave tibial insert
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Posterior-stabilized (PS) insert
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Concave tibial insert with resection of the posterior cruciate ligament
Number of subjects: 53
Study: 16883906

Group type: EXPERIMENTAL
Intervention: Shizhang Cataplasm (SC) for excessive syndrome (ES) type
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Xuzhang Cataplasm (XC) for deficient syndrome (DS) type
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group for excessive syndrome (ES) type
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group for deficient syndrome (DS) type
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Both SC and XC
Number of subjects: 77
Study: 12008859

Group type: EXPERIMENTAL
Intervention: Anakinra 30 to 150 mg subcutaneously each day for 24 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Etanercept 25 mg subcutaneously twice weekly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Infliximab 3 to 10 mg/kg intravenously every 4 or 8 weeks
Number of subjects: 0
Study: 10594397

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 1351

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 1351
Study: 8838789

Group type: EXPERIMENTAL
Intervention: Acute pain syndromes
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Chronic pain syndromes
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Specific pain types (tension and pain in extremities, spasms, low back pain, Lhermitte's sign, neuralgia)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Deterioration of disability
Number of subjects: 49
Study: 2305700

Group type: EXPERIMENTAL
Intervention: High exercise work rates (80‐90% of peak VO2) for 25 min/d
Number of subjects: 27

Group type: COMPARATOR
Intervention: Low exercise work rates (40‐50% of peak VO2) for 50 min/d
Number of subjects: 27
Study: 7022517

Group type: EXPERIMENTAL
Intervention: Clomipramine hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0